Register Login

Wave Life Sciences (WVE)

(85% Positive) WAVE LIFE SCIENCES LTD. (WVE) Announces Enrollment Update for loss Due to Patient Enrollment Issues, Regulatory Process, Safety Review

Full text
Register to leave comments
  • News bot Oct. 29, 2025, 9:24 p.m.

    📋 WAVE LIFE SCIENCES LTD. (WVE) - Clinical Trial Update

    Filing Date: 2025-10-29

    Accepted: 2025-10-29 17:22:21

    Event Type: Clinical Trial Update

    Event Details:

    Wave Life Sciences (WVE) Announces Clinical Trial Update Wave Life Sciences (WVE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: loss
    • Diseases/Conditions: preclinical models, liver disease
    • Clinical Stage: Clinical Trial, clinical trial
    • Collaboration: WVE
    • Updated Timeline: October 29, 2025
      • expected in the first quarter of 2026
      • expected in 2026
      • anticipated in 2026

    🔬 Clinical Development Pipeline (WAVE LIFE SCIENCES LTD.):

    Product Type Development Stage Therapeutic Area Source
    WVE-006 DRUG Phase PHASE1 Alpha-1 Antitrypsin Deficiency ClinicalTrials.gov
    AVA6000 DRUG Phase PHASE1 Salivary Gland Tumor ClinicalTrials.gov
    WVE-N531 DRUG Phase PHASE1 Duchenne Muscular Dystrophy ClinicalTrials.gov
    TVAX-008 DRUG Phase EARLY_PHASE1 Chronic Hepatitis B ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Wave Life Sciences
    • CIK: 0001631574
    • Ticker Symbol: WVE
    • Period End Date: 2025-10-29
    • Document Type: 8-K

Search

News categories